TABLE 1

FDA-approved drugs with CYP2D6 genotype/phenotype considerations specified in the prescribing information

DrugIndicationPhenotype of ConcernPrescribing Information
AmitriptylineDepressionPM, IM, UMMonitor TCA plasma levels
AmoxapineDepressionPM, IM, UMMonitor TCA plasma levels
AripiprazoleSchizophrenia and bipolar disorderPMDose modification
Aripiprazole lauroxilSchizophreniaPMDose modification
AtomoxetineADHDPMAdjust titration interval and dose modification
BrexpiprazoleMajor depressive disorder and schizophreniaPMDose modification
CarvedilolMild to severe chronic heart failurePMInformative
CevimelineSjogren syndromePMUse with caution
ClomipramineObsessive-compulsion disorderPMInformative
ClozapineTreatment-resistant schizophrenia and reducing suicidal behavior in patients with schizophrenia or schizoaffective disorderPMDose modification
Codeine SulfateRelief of mild to moderate severe painUMUse with Caution
EliglustatGaucher diseasePM, IM, NM, UMDose modification based on phenotype
DarifenacinOveractive bladderUM, PMInformative
DesipramineDepressionPMInformative
DeutetrabenazineChorea associated with Huntington diseasePMDose modification
Dextromethorphan/quinidinePseudobulbar affectPMDetermine risk for toxicity
dextromethorphan hydrobromide and bupropion hydrochlorideMajor depressive disorderPMDose modification
DonepezilAlzheimer diseaseUM, PMInformative
DoxepinDepression, anxiety, and sleep disordersPMInformative
FesoterodineOveractive bladderPMInformative
FlibanserinPremenopausal women who acquire generalized hypoactive sexual desire disorderPMMonitor for adverse events
Fluoxetine/olanzapineDepressive episodes associated with bipolar I disorder in adults and treatment resistant depressionPMInformative
FluvoxamineObsession and compulsions in patients with OCDPMUse with caution
GefitinibMetastatic non–small cell lung cancer whose tumor have EGFR exon 19 deletions or exon 21 (L858R) substitution mutationsPMMonitor for adverse reaction
IloperidoneSchizophreniaPMDose modification
ImipramineDepression and childhood enuresisPMInformative
IofexidineOpioid withdrawal symptomsPMMonitor for adverse events
MetoclopramideGastroesophageal refluxPMDose modification
MirabegronOveractive bladderPMInformative
NortriptylineMajor depressive disorder and other psychiatric disordersPMInformative
OliceridineManagement of acute severe painPMMonitor for adverse events
PerphenazineSchizophrenia and severe nausea and vomitingPMInformative
PimozideTourette syndromePMDose modification
PitolisantExcessive daytime sleepiness in adult patients with narcolepsyPMDose modification
PropafenoneAtrial fibrillation who do not have structural heart disease, paroxysmal supraventricular tachycardiaa associated with disabling symptoms in patients who do not have structural heart disease, and life-threatening ventricular arrhythmiasPMInformative
ProtriptylineDepressionPMInformative
TamoxifenEstrogen receptor–positive metastatic breast cancer, early-stage estrogen receptor–positive breast cancerPMInformative
TamsulosinSigns and symptoms of benign prostatic hyperplasiaPMUse with Caution
TetrabenazineHuntington diseasePM, NMDose modification based on PM status
ThioridazineSchizophreniaPMContraindicated in PM
TolterodineOveractive bladderPMInformative
TramadolManagement of moderate to moderately severe chronic painUMWarning
TrimipramineDepressionPMInformative
ValbenazineTardive dyskinesiaPMDose modification
VenlafaxineMajor depressive disorder, generalized anxiety disorder, social anxiety disorder, panic disorderPMInformative
ViloxazineAttention deficit hyperactivity disorderPMInformative
VortioxetineMajor depressive disorderPMDose modification
  • ADHD, attention-deficit/hyperactivity disorder; EGFR, epidermal growth factor receptor; OCD, obsessive-compulsive disorder; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; UM, ultra-rapid metabolizer.